Amino acid Metabolism Disorders Treatment Market By Indication, By Product, By Distribution channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Phenylketonuria
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Maple syrup urine disease
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Citrullinemia
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Homocystinuria
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Argininosuccinic aciduria
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country

CHAPTER 5: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT
5.1 Overview
5.1.1 Market size and forecast
5.2 Folic Acid
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Vitamin B6 and B12
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Arginine
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Thiamine
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Betaine
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Sapropterin
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Others
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country

CHAPTER 6: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 DrU.S.ores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 DrU.S.ores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
6.3.4.1 Prescription drug Market size and forecast, by region
6.3.4.2 OTC drug Market size and forecast, by region
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Indication
7.2.3 North America Market size and forecast, by Product
7.2.4 North America Market size and forecast, by Distribution channel
7.2.4.1 North America DrU.S.ores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Indication
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Indication
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Indication
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Indication
7.3.3 Europe Market size and forecast, by Product
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.4.1 Europe DrU.S.ores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Indication
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Indication
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Indication
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Indication
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Indication
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Indication
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Indication
7.4.3 Asia-Pacific Market size and forecast, by Product
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.4.1 Asia-Pacific DrU.S.ores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Indication
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Indication
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Distribution channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Indication
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Distribution channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Indication
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Indication
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Indication
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Indication
7.5.3 LAMEA Market size and forecast, by Product
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.4.1 LAMEA DrU.S.ores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Indication
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Indication
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Indication
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Indication
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Distribution channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 AMINO GmbH
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Civentichem, LLC, Ltd.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 GlaxoSmithKline PLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Koninklijke DSM N. V.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Kyowa Hakko Kirin Co., Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck KGaA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Recordati S. p. A.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Shine Star (Hubei) Biological Engineering Co.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 BioMarin Pharmaceutical Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Teva Pharmaceutical Industries Ltd.
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments

List of Tables
Table 1. Global Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 2. Amino Acid Metabolism Disorders Treatment Market, for Phenylketonuria, by Region, 2021-2031 ($Million)
Table 3. Amino Acid Metabolism Disorders Treatment Market for Phenylketonuria, by Country, 2021-2031 ($Million)
Table 4. Amino Acid Metabolism Disorders Treatment Market, for Maple Syrup Urine Disease, by Region, 2021-2031 ($Million)
Table 5. Amino Acid Metabolism Disorders Treatment Market for Maple Syrup Urine Disease, by Country, 2021-2031 ($Million)
Table 6. Amino Acid Metabolism Disorders Treatment Market, for Citrullinemia, by Region, 2021-2031 ($Million)
Table 7. Amino Acid Metabolism Disorders Treatment Market for Citrullinemia, by Country, 2021-2031 ($Million)
Table 8. Amino Acid Metabolism Disorders Treatment Market, for Homocystinuria, by Region, 2021-2031 ($Million)
Table 9. Amino Acid Metabolism Disorders Treatment Market for Homocystinuria, by Country, 2021-2031 ($Million)
Table 10. Amino Acid Metabolism Disorders Treatment Market, for Argininosuccinic Aciduria, by Region, 2021-2031 ($Million)
Table 11. Amino Acid Metabolism Disorders Treatment Market for Argininosuccinic Aciduria, by Country, 2021-2031 ($Million)
Table 12. Global Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 13. Amino Acid Metabolism Disorders Treatment Market, for Folic Acid, by Region, 2021-2031 ($Million)
Table 14. Amino Acid Metabolism Disorders Treatment Market for Folic Acid, by Country, 2021-2031 ($Million)
Table 15. Amino Acid Metabolism Disorders Treatment Market, for Vitamin B6 and B12, by Region, 2021-2031 ($Million)
Table 16. Amino Acid Metabolism Disorders Treatment Market for Vitamin B6 and B12, by Country, 2021-2031 ($Million)
Table 17. Amino Acid Metabolism Disorders Treatment Market, for Arginine, by Region, 2021-2031 ($Million)
Table 18. Amino Acid Metabolism Disorders Treatment Market for Arginine, by Country, 2021-2031 ($Million)
Table 19. Amino Acid Metabolism Disorders Treatment Market, for Thiamine, by Region, 2021-2031 ($Million)
Table 20. Amino Acid Metabolism Disorders Treatment Market for Thiamine, by Country, 2021-2031 ($Million)
Table 21. Amino Acid Metabolism Disorders Treatment Market, for Betaine, by Region, 2021-2031 ($Million)
Table 22. Amino Acid Metabolism Disorders Treatment Market for Betaine, by Country, 2021-2031 ($Million)
Table 23. Amino Acid Metabolism Disorders Treatment Market, for Sapropterin, by Region, 2021-2031 ($Million)
Table 24. Amino Acid Metabolism Disorders Treatment Market for Sapropterin, by Country, 2021-2031 ($Million)
Table 25. Amino Acid Metabolism Disorders Treatment Market, for Others, by Region, 2021-2031 ($Million)
Table 26. Amino Acid Metabolism Disorders Treatment Market for Others, by Country, 2021-2031 ($Million)
Table 27. Global Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 28. Amino Acid Metabolism Disorders Treatment Market, for Hospital Pharmacies, by Region, 2021-2031 ($Million)
Table 29. Amino Acid Metabolism Disorders Treatment Market for Hospital Pharmacies, by Country, 2021-2031 ($Million)
Table 30. Amino Acid Metabolism Disorders Treatment Market, for DrU.S.ores and Retail Pharmacies, by Region, 2021-2031 ($Million)
Table 31. Amino Acid Metabolism Disorders Treatment Market for DrU.S.ores and Retail Pharmacies, by Country, 2021-2031 ($Million)
Table 32. Global DrU.S.ores and Retail Pharmacies Amino Acid Metabolism Disorders Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 33. Amino Acid Metabolism Disorders Treatment Market, for Prescription Drug, by Region, 2021-2031 ($Million)
Table 34. Amino Acid Metabolism Disorders Treatment Market, for OTC Drug, by Region, 2021-2031 ($Million)
Table 35. Amino Acid Metabolism Disorders Treatment Market, for Online Providers, by Region, 2021-2031 ($Million)
Table 36. Amino Acid Metabolism Disorders Treatment Market for Online Providers, by Country, 2021-2031 ($Million)
Table 37. Amino Acid Metabolism Disorders Treatment Market, by Region, 2021-2031 ($Million)
Table 38. North America Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 39. North America Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 40. North America Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 41. North America DrU.S.ores and Retail Pharmacies Amino Acid Metabolism Disorders Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 42. North America Amino Acid Metabolism Disorders Treatment Market, by Country, 2021-2031 ($Million)
Table 43. U.S. Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 44. U.S. Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 45. U.S. Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 46. Canada Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 47. Canada Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 48. Canada Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 49. Mexico Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 50. Mexico Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 51. Mexico Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 52. Europe Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 53. Europe Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 54. Europe Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 55. Europe DrU.S.ores and Retail Pharmacies Amino Acid Metabolism Disorders Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 56. Europe Amino Acid Metabolism Disorders Treatment Market, by Country, 2021-2031 ($Million)
Table 57. Germany Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 58. Germany Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 59. Germany Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 60. France Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 61. France Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 62. France Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 63. UK Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 64. UK Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 65. UK Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 66. Italy Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 67. Italy Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 68. Italy Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 69. Spain Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 70. Spain Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 71. Spain Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 72. Rest of Europe Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 73. Rest of Europe Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 74. Rest of Europe Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 75. Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 76. Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 77. Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 78. Asia-Pacific DrU.S.ores and Retail Pharmacies Amino Acid Metabolism Disorders Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 79. Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Country, 2021-2031 ($Million)
Table 80. Japan Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 81. Japan Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 82. Japan Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 83. China Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 84. China Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 85. China Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 86. Australia Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 87. Australia Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 88. Australia Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 89. India Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 90. India Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 91. India Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 92. South Korea Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 93. South Korea Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 94. South Korea Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 95. Rest of Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 96. Rest of Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 97. Rest of Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 98. LAMEA Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 99. LAMEA Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 100. LAMEA Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 101. LAMEA DrU.S.ores and Retail Pharmacies Amino Acid Metabolism Disorders Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 102. LAMEA Amino Acid Metabolism Disorders Treatment Market, by Country, 2021-2031 ($Million)
Table 103. Brazil Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 104. Brazil Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 105. Brazil Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 106. Saudi Arabia Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 107. Saudi Arabia Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 108. Saudi Arabia Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 109. South Africa Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 110. South Africa Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 111. South Africa Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 112. Rest of LAMEA Amino Acid Metabolism Disorders Treatment Market, by Indication, 2021-2031 ($Million)
Table 113. Rest of LAMEA Amino Acid Metabolism Disorders Treatment Market, by Product, 2021-2031 ($Million)
Table 114. Rest of LAMEA Amino Acid Metabolism Disorders Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 115. Amino GmbH: Company Snapshot
Table 116. Amino GmbH: Operating Segments
Table 117. Amino GmbH: Product Portfolio
Table 118. Amino GmbH: Net Sales
Table 119. Amino GmbH: Key Strategies
Table 120. Civentichem, LLC, Ltd.: Company Snapshot
Table 121. Civentichem, LLC, Ltd.: Operating Segments
Table 122. Civentichem, LLC, Ltd.: Product Portfolio
Table 123. Civentichem, LLC, Ltd.: Net Sales
Table 124. Civentichem, LLC, Ltd.: Key Strategies
Table 125. GlaxoSmithKline PLC: Company Snapshot
Table 126. GlaxoSmithKline PLC: Operating Segments
Table 127. GlaxoSmithKline PLC: Product Portfolio
Table 128. GlaxoSmithKline PLC: Net Sales
Table 129. GlaxoSmithKline PLC: Key Strategies
Table 130. Koninklijke DSM N. V.: Company Snapshot
Table 131. Koninklijke DSM N. V.: Operating Segments
Table 132. Koninklijke DSM N. V.: Product Portfolio
Table 133. Koninklijke DSM N. V.: Net Sales
Table 134. Koninklijke DSM N. V.: Key Strategies
Table 135. Kyowa Hakko Kirin Co. Ltd.: Company Snapshot
Table 136. Kyowa Hakko Kirin Co. Ltd.: Operating Segments
Table 137. Kyowa Hakko Kirin Co. Ltd.: Product Portfolio
Table 138. Kyowa Hakko Kirin Co. Ltd.: Net Sales
Table 139. Kyowa Hakko Kirin Co. Ltd.: Key Strategies
Table 140. Merck KGaA: Company Snapshot
Table 141. Merck KGaA: Operating Segments
Table 142. Merck KGaA: Product Portfolio
Table 143. Merck KGaA: Net Sales
Table 144. Merck KGaA: Key Strategies
Table 145. Pfizer, Inc.: Company Snapshot
Table 146. Pfizer, Inc.: Operating Segments
Table 147. Pfizer, Inc.: Product Portfolio
Table 148. Pfizer, Inc.: Net Sales
Table 149. Pfizer, Inc.: Key Strategies
Table 150. Recordati S. P. A.: Company Snapshot
Table 151. Recordati S. P. A.: Operating Segments
Table 152. Recordati S. P. A.: Product Portfolio
Table 153. Recordati S. P. A.: Net Sales
Table 154. Recordati S. P. A.: Key Strategies
Table 155. Sanofi: Company Snapshot
Table 156. Sanofi: Operating Segments
Table 157. Sanofi: Product Portfolio
Table 158. Sanofi: Net Sales
Table 159. Sanofi: Key Strategies
Table 160. Shine Star (Hubei) Biological Engineering Co.: Company Snapshot
Table 161. Shine Star (Hubei) Biological Engineering Co.: Operating Segments
Table 162. Shine Star (Hubei) Biological Engineering Co.: Product Portfolio
Table 163. Shine Star (Hubei) Biological Engineering Co.: Net Sales
Table 164. Shine Star (Hubei) Biological Engineering Co.: Key Strategies
Table 165. Biomarin Pharmaceutical Inc.: Company Snapshot
Table 166. Biomarin Pharmaceutical Inc.: Operating Segments
Table 167. Biomarin Pharmaceutical Inc.: Product Portfolio
Table 168. Biomarin Pharmaceutical Inc.: Net Sales
Table 169. Biomarin Pharmaceutical Inc.: Key Strategies
Table 170. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 171. Teva Pharmaceutical Industries Ltd.: Operating Segments
Table 172. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 173. Teva Pharmaceutical Industries Ltd.: Net Sales
Table 174. Teva Pharmaceutical Industries Ltd.: Key Strategies

List of Figures
Figure 1. Amino Acid Metabolism Disorders Treatment Market Segmentation
Figure 2. Amino Acid Metabolism Disorders Treatment Market, 2021-2031
Figure 3. Amino Acid Metabolism Disorders Treatment Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Amino Acid Metabolism Disorders Treatment Mark.:Drivers, Restraints and Opportunities
Figure 12. Amino Acid Metabolism Disorders Treatment Market, By Indication, 2021(%)
Figure 13. Comparative Share Analysis of Phenylketonuria Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 14. Comparative Share Analysis of Maple Syrup Urine Disease Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 15. Comparative Share Analysis of Citrullinemia Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 16. Comparative Share Analysis of Homocystinuria Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 17. Comparative Share Analysis of Argininosuccinic Aciduria Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 18. Amino Acid Metabolism Disorders Treatment Market, By Product, 2021(%)
Figure 19. Comparative Share Analysis of Folic Acid Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Vitamin B6 and B12 Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 21. Comparative Share Analysis of Arginine Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 22. Comparative Share Analysis of Thiamine Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 23. Comparative Share Analysis of Betaine Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Sapropterin Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 25. Comparative Share Analysis of Others Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 26. Amino Acid Metabolism Disorders Treatment Market, By Distribution Channel, 2021(%)
Figure 27. Comparative Share Analysis of Hospital Pharmacies Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 28. Comparative Share Analysis of Drug Stores and Retail Pharmacies Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 29. Comparative Share Analysis of Online Providers Amino Acid Metabolism Disorders Treatment Market, 2021-2031(%)
Figure 30. Amino Acid Metabolism Disorders Treatment Market by Region, 2021
Figure 31. U.S. Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 32. Canada Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 33. Mexico Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 34. Germany Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 35. France Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 36. Uk Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 37. Italy Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 38. Spain Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 39. Rest of Europe Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 40. Japan Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 41. China Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 42. Australia Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 43. India Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 44. South Korea Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 45. Rest of Asia-Pacific Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 46. Brazil Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 47. Saudi Arabia Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 48. South Africa Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 49. Rest of LAMEA Amino Acid Metabolism Disorders Treatment Market, 2021-2031($Million)
Figure 50. Top Winning Strategies, by Year
Figure 51. Top Winning Strategies, by Development
Figure 52. Top Winning Strategies, by Company
Figure 53. Product Mapping of Top 10 Players
Figure 54. Competitive Dashboard
Figure 55. Competitive Heatmap of Top 10 Key Players
Figure 56. Amino Gmb.: Net Sales, ($Million)
Figure 57. Civentichem, LLC, Ltd.: Net Sales, ($Million)
Figure 58. GlaxoSmithKline pl.: Net Sales, ($Million)
Figure 59. Koninklijke Dsm N.V.: Net Sales, ($Million)
Figure 60. Kyowa Hakko Kirin Co. Ltd.: Net Sales, ($Million)
Figure 61. Merck Kga.: Net Sales, ($Million)
Figure 62. Pfizer, Inc.: Net Sales, ($Million)
Figure 63. Recordati S.P.A.: Net Sales, ($Million)
Figure 64. Sanof.: Net Sales, ($Million)
Figure 65. Shine Star (Hubei) Biological Engineering Co.: Net Sales, ($Million)
Figure 66. Biomarin Pharmaceutical Inc.: Net Sales, ($Million)
Figure 67. Teva Pharmaceutical Industries Ltd.: Net Sales, ($Million)

Executive Summary

According to the report, “Amino acid Metabolism Disorders Treatment Market," the amino acid metabolism disorders treatment market was valued at $630.92 million in 2021, and is estimated to reach $961.8 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.

Metabolism is the process which the body uses to make energy from the food eaten. Food is made up of proteins, carbohydrates, and fats. The digestive system breaks the food parts down into sugars and acids which are also called as the body's fuel. The body can use this fuel right away, or it can store the energy in the body. If a person has a metabolic disorder, then the metabolism process gets harmed and impacted severely. Amino acids are the organic compounds which contains carboxyl and amine functional groups attached to carbon chain. Amino acid metabolism disorders occurs due to excessive build-up of amino acids such as methionine, homocystine, and phenylalanine in the body. This is attributed to improper metabolism of amino acids. The excessive buildup of amino acids and toxic substances can cause health problems such as brain damage, neurological problems, development problems, depression, and hyperactive disorders. One group of amino acid metabolism disorders include phenylketonuria (PKU) and maple syrup urine disease. Amino acids are "building blocks" that join together to form proteins. If people have one of these disorders, their body may have trouble breaking down certain amino acids. There may also be a problem getting the amino acids into the cells. These problems cause a buildup of harmful substances in the body. That can lead to serious, sometimes life-threatening, health problems. These disorders are usually inherited. A baby who is born with this disease may not have any symptoms right away. Its because the disorders can be so serious. The early diagnosis and treatment are critical. Newborn babies get screened for many of these symptoms by using blood tests. The treatments of the amino acid metabolism disorders may include special diets, medicines, and supplements. Some babies may also need additional treatments if there are complications.

Factors that drive growth of global amino acid metabolism disorders treatment market size include the increase in prevalence of amino acid metabolism disorders, availability of various treatments options, rise in healthcare expenditure, and surge in early stage newborn screening for amino acid metabolism disorders diagnosis. In addition, increase in healthcare expenditure also contributes towards the global amino acid metabolism disorders treatment market growth. However, high cost of treatments for amino acid metabolism disorders is expected to hinder the growth of the amino acid metabolism disorders treatment market size.

The COVID-19 pandemic affected the amino acid metabolism disorders treatment industry in a negative way, like various other pharmaceutical industries were affected. This was due to the significant decline in demand for the amino acid metabolism disorders treatments across several sectors, particularly the health and pharmaceutical sector. The main cause of the interruptions experienced by government, as government was majorly involved in the disease spread preventive measures finding. As a result, the COVID-19 outbreak will slowdown the amino acid metabolism disorders treatment industry growth, which will have a negative effect on the market's value in 2022 and beyond.

By product type, the market is divided into folic acid, vitamin B6 and B12, arginine, thiamine, betaine, sapropterin, and others. The sapropterin segment exhibited the highest growth in 2021, owing to amino acid metabolism disorders treatment market trends like increase in prevalence of phenylketonuria and increase in demand for sapropterin in developed countries such as the U.S. and Germany. However, betaine segment is expected to register highest CAGR of 5.4% from 2022 to 2031, owing to increase in product offering for betaine by key market players.

By indication, the market is classified as phenylketonuria, maple syrup urine disease, citrullinemia, homocystinuria, and argininosuccinic aciduria. The phenylketonuria segment exhibited the highest growth in 2021, owing to increase in prevalence of phenylketonuria and mandatory newborn screening for the diagnosis of phenylketonuria and other amino acid metabolism disorders. However, maple syrup urine disease segment is expected to register highest CAGR of 5.5% from 2022 to 2031, owing to increase in prevalence of maple syrup urine disease and development of new therapies for the treatment of maple syrup urine disease.

By distribution channel, the market is classified as hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment dominated the market in 2021 and is expected to remain dominant during the forecast period. The market growth of this segment driven by increase sell of prescription drugs and OTC drugs. However, online providers is expected to register highest CAGR of 6.0% from 2022 to 2031, owing to shift of patients preference to buy medicine online since the covid pandemic period.

Region wise, North America has the highest amino acid metabolism disorders treatment market share in 2021, and is expected to maintain its lead during the forecast period, owing to increase in demands for sapropterin and Kuvan for amino acid metabolism disorders treatments. Moreover, the North America advances due to availability of treatments and well established healthcare infrastructure. However, Asia-Pacific is expected to register highest CAGR of 5.5% during the amino acid metabolism disorders treatment market forecast period, owing to increase in prevalence amino acid metabolism disorders and rise in patients seeking treatment for amino acid metabolism disorders.

KEY FINDINGS OF STUDY

• Based on product type, the sapropterin segment was highest contributor to the market in 2021.
• On the basis of indication, phenylketonuria dominated the market in 2021, and is expected to continue this trend during the forecast period.
• Based on distribution channel, drug stores and retail pharmacies dominated the market in 2021, and is expected to grow at a CAGR of 3.9% during the amino acid metabolism disorders treatment market analysis period.
• Based on region, North America generated the largest revenue share in 2021, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

• AMINO GmbH
• Civentichem, LLC, Ltd.
• GlaxoSmithKline PLC
• Koninklijke DSM N.V.
• Kyowa Hakko Kirin Co., Ltd.
• Merck KGaA
• Pfizer, Inc.
• Recordati S.p.A.
• Sanofi
• Shine Star (Hubei) Biological Engineering Co.
• BioMarin Pharmaceutical Inc.
• Teva Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.